hyo cheol kim

Solitary fibrous tumors (SFT) are rare soft tissue tumors with a typically benign clinical course; however, up to 35% of SFT exhibit metastasis, resulting in a poor prognosis. The management of hepatic metastasis of SFT is yet to be established because of its rarity of cases.

Herein, we report the clinical results of 13 transarterial chemoembolization (TACE) sessions for hepatic metastasis in 5 patients with SFT.

Patients with hepatic metastases from SFT who underwent TACE between May 2005 and April 2021 were retrospectively reviewed. Tumorresponse was evaluated using the modified response evaluation criteria in solid tumors (mRECIST).

Five patients (one male, mean age: 59.2 years) underwent 13 TACE sessions, resulting in four partial responses (PR, 30.8%), four stable disease cases (30.8%), and five progressive disease cases (38.5%). No severe complications occurred. Four of seven sessions (57.1%) of selective TACE showed partial response (PR). The mean progression-free survival (PFS) was 2.3 months (range: 0 - 8 months), and for sessions with PR, the mean PFS was 6.3 months (range: 3 - 8 months). The mean overall survival was 32.7 months (range: 18 - 44 months).

This report suggests that TACE might be a potentially safe treatment option for hepatic metastasis of SFT, and it could offer a benefit in controlling local tumor growth in cases where selective TACE is applicable.

Malfunctions of totally implantable central venous ports (TICVPs) have become a problem, as the usage of TICVPs has increased enormously..
This study evaluated factors related with catheter malfunctions of TICVPs..
Patients and Between January 2010 and June 2012, 1,740 TICVPs in 1,740 patients (874 men and 866 women) with an average age of 57.7 ± 12.8 years (range: 15 - 91 years) were implanted by an interventional radiology team at our institute. Catheter malfunctions were retrospectively analyzed. In the prospective study, we randomly allocated 176 patients to two kinds of TICVPs in a 1:1 assignment ratio. The primary outcome was the malfunction of TICVPs..
In the retrospective study, the 32 malfunctioning TICVPs were caused by fibrin sheath formations (n = 15), chamber thrombosis (n = 8), TICVP rotation (n = 5), catheter migration (n = 2), and blood clots within the catheters (n = 2). Multivariate analysis showed that being female was a significant factor for poor patency rates of TICVPs (hazard ratio: 5.06; 95% confidence interval (CI) 1.32 - 19.46, P = 0.018). In the prospective study, two chamber thromboses occurred in Celsite® (n = 1) and Humanport® (n = 1). The primary patency rates of both Celsite® and Humanport® were 98.9% at 6 months, respectively..
Our data suggest that catheter malfunctions of TICVPs are more common in females than males. The incidence of TICVP malfunctions does not differ between the two devices (Celsite® vs. Humanport®)..